Innovent Biologics (IVBXF,1801.HK) announced that the New Drug Application for TABOSUN has been approved by China's National Medical Products Administration, in combination with sintilimab as neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high or mismatch repair deficient colon cancer. TABOSUN is the world's first approved CTLA-4 mAb for neoadjuvant treatment of colon cancer.
The approval is based on results from the randomized, controlled, multicenter, pivotal Phase 3 clinical trial, which evaluated the safety and efficacy of ipilimumab N01 combined with sintilimab as neoadjuvant therapy compared with direct radical surgery for MSI-H/dMMR colon cancer.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.